Cancers, Vol. 14, Pages 570: Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases
Cancers, Vol. 14, Pages 570: Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases
Cancers doi: 10.3390/cancers14030570
Authors:
Beatrice J. Sun
Byrne Lee
Gastric cancer carries a poor prognosis and is a leading cause of cancer-related mortality worldwide. Patients with gastric cancer who develop peritoneal metastases have an even more dismal prognosis, with median survival time measured in months. Since studies have demonstrated that systemic chemotherapy has poor penetration into the peritoneum, multimodal treatment with intraperitoneal chemotherapy has been proposed for the treatment of peritoneal metastases and has become the foundation for newer therapeutic techniques and clinical trials. These include heated intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS), which involves the application of heated chemotherapy into the abdomen with or without tumor debulking surgery; normothermic intraperitoneal chemotherapy (NIPEC), in which non-heated chemotherapy can be delivered into the abdomen via a peritoneal port allowing for repeat dosing; and pressurized intraperitoneal aerosolized chemotherapy (PIPAC), a newer technique of pressurized and aerosolized chemotherapy delivered into the abdomen during laparoscopy. Early results with intraperitoneal chemotherapy have shown promise in increasing disease-free and overall survival in select patients. Additionally, there may be a palliative effect of these regional therapies. In this ...
Source: Cancers - Category: Cancer & Oncology Authors: Beatrice J. Sun Byrne Lee Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Gastric (Stomach) Cancer | Gastroenterology | Laparoscopy | Palliative | Peritoneal Cancer | Study